- Home
- RFMZ vs ALXO Comparison
RFMZ vs ALXO Comparison
Compare RFMZ & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFMZ
- ALXO
- Stock Information
- Founded
- RFMZ 2021
- ALXO 2015
- Country
- RFMZ United States
- ALXO United States
- Employees
- RFMZ N/A
- ALXO N/A
- Industry
- RFMZ Trusts Except Educational Religious and Charitable
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- RFMZ Finance
- ALXO Health Care
- Exchange
- RFMZ Nasdaq
- ALXO Nasdaq
- Market Cap
- RFMZ 344.8M
- ALXO 358.4M
- IPO Year
- RFMZ N/A
- ALXO 2020
- Fundamental
- Price
- RFMZ $14.22
- ALXO $1.91
- Analyst Decision
- RFMZ
- ALXO Strong Buy
- Analyst Count
- RFMZ 0
- ALXO 7
- Target Price
- RFMZ N/A
- ALXO $14.83
- AVG Volume (30 Days)
- RFMZ 76.6K
- ALXO 928.2K
- Earning Date
- RFMZ 01-01-0001
- ALXO 08-08-2024
- Dividend Yield
- RFMZ 7.43%
- ALXO N/A
- EPS Growth
- RFMZ N/A
- ALXO N/A
- EPS
- RFMZ 0.65
- ALXO N/A
- Revenue
- RFMZ N/A
- ALXO N/A
- Revenue This Year
- RFMZ N/A
- ALXO N/A
- Revenue Next Year
- RFMZ N/A
- ALXO N/A
- P/E Ratio
- RFMZ $21.49
- ALXO N/A
- Revenue Growth
- RFMZ N/A
- ALXO N/A
- 52 Week Low
- RFMZ $11.28
- ALXO $1.88
- 52 Week High
- RFMZ $14.57
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- RFMZ 49.92
- ALXO 22.94
- Support Level
- RFMZ $14.16
- ALXO $2.32
- Resistance Level
- RFMZ $14.32
- ALXO $2.59
- Average True Range (ATR)
- RFMZ 0.12
- ALXO 0.18
- MACD
- RFMZ -0.00
- ALXO 0.11
- Stochastic Oscillator
- RFMZ 60.61
- ALXO 3.53
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.